Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aastrom Moves Cell Therapy Into Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech talked about its late-stage clinical plans during a second quarter conference call.

You may also be interested in...



Aastrom Adds Revenues Through $6.5M Regen Med Buy From Sanofi

The stem cell company will use revenues from the already-marketed products to continue funding the late-stage stem cell therapy in its pipeline and help it build out its commercial organization.

Aastrom Stands Behind Its Decision To Shift Gears In Late Stages

The Michigan biotech is undergoing a complete restructuring as it cans its lead program and new management implements a different vision for the company.

France's Cellectis To Acquire Cellartis To Produce A Leader In Stem Cell Technologies

The genome engineering company, Cellectis, is to acquire the Swedish human embryonic stem cell firm Cellartis in a €30 million deal expected to complete at the end of October.

Related Content

Topics

UsernamePublicRestriction

Register

PS072641

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel